A bipartisan congressional report estimates overdose deaths cost the United States $1 trillion yearly; 4 states announce plans to lift their statewide mask mandates for schools; study finds greater risk of pregnancy complications in expectant mothers with moderate COVID-19 symptoms.
A new bipartisan congressional report published today found that drug overdoses, primarily those stemming from synthetic opioids, have cost the United States approximately $1 trillion yearly. ABC News reports that drug overdose deaths have more than doubled in recent years, rising from 44,000 to 2013 to over 100,000 between May 2020 and April 2021. As opioid drugs, particularly fentanyl, continue to drive record overdose deaths, a bipartisan congressional commission advocated for a multipronged strategy and cabinet-level leadership to counter the worsening overdose epidemic.
NPR reports that 4 states, Oregon, New Jersey, Connecticut, and Delaware, have announced plans this week to lift their respective statewide mask mandates for schools. The loosening COVID-19 restrictions are set to take effect in Connecticut on February 28, the earliest of the 4 states, with Oregon and Delaware noted as the latest to set plans for March 31. The mask mandate in New Jersey will lift for both students and employees beginning March 7, with districts allowed to require masking thereafter to control any spikes in infections.
As reported by USA Today, a study funded by the National Institutes of Health highlighted the protective benefits of vaccines for expectant mothers and their babies, in utero and after birth. Including 13,000 expectant mothers in the analysis, of which 2400 were infected, findings indicated that pregnant women with moderate COVID-19 symptoms were at greater risk for pregnancy complications than those not infected or with mild to no symptoms. Complications included higher chances of requiring cesarean section, delivering preterm, and mortality around the time of birth.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More